Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Buy rating on NeoGenomics (NASDAQ:NEO) and maintained a price target of $18.
September 24, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Buy rating on NeoGenomics, maintaining a price target of $18. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100